- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01744860
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
25 februari 2016 uppdaterad av: Hoffmann-La Roche
Evaluation of Concordance Between the Methods Used in INCa Platforms and the Cobas® 4800 BRAF V600 Mutation Test for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting
This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples.
No patients will be enrolled in this study.
Data will be collected for approximately 6 months.
Studieöversikt
Status
Avslutad
Betingelser
Studietyp
Observationell
Inskrivning (Faktisk)
420
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Boulogne Billancourt, Frankrike, 92104
-
Colmar, Frankrike, 68024
-
Lille, Frankrike, 59037
-
Lyon, Frankrike, 69437
-
Marseille, Frankrike, 13015
-
Montpellier, Frankrike, 34295
-
Nantes, Frankrike, 44093
-
Paris, Frankrike, 75010
-
Pessac, Frankrike, 33604
-
Rouen, Frankrike, 76031
-
Vandoeuvre Les Nancy, Frankrike, 54511
-
Villejuif, Frankrike, 94505
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Testmetod
Sannolikhetsprov
Studera befolkning
No patients are enrolled in this study.
Use of melanoma tumor samples.
Beskrivning
Inclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Histologically proven melanoma tumor sample
- Any type of tumor sample: biopsy or surgical specimen of primary tumor or metastasis
- Tumor samples must be fixed and paraffin-embedded.
Exclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Fixative unknown
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
INCa molecular genetics laboratory "in-house" methods
BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods
|
|
Cobas 4800 Mutation Test
BRAF V600 mutations were analysed using Cobas 4800 mutation test
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories
Tidsram: Up to 6 months
|
BRAF V600 mutation status was determined by INCa molecular laboratories "in-house" methods and Cobas 4800 BRAF V600 mutation test.
Samples were analysed as V600 mutation, No V600 mutation and Non evaluable.
Additionally, the type of V600 mutation (E, K, R, D, E2, other V600 mutation, not specified) was also evaluated only by INCa molecular laboratory "in-house" method.
|
Up to 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Tumor Sample Characteristics-Type of Tumor Sample
Tidsram: Up to 6 months
|
The type of tumor sample used for evaluation of BRAF V600 mutation whether it was a biopsy or surgical specimen were reported
|
Up to 6 months
|
|
Tumor Sample Characteristics - Source of Tumor Sample
Tidsram: Up to 6 months
|
The source of tumor sample for BRAF V600 mutation detection whether taken from internal or external pathology laboratory were reported
|
Up to 6 months
|
|
Type of Pathology Laboratory Performing the Fixation or Embedding-Pre-analytical Method
Tidsram: Up to 6 months
|
The external or internal pathology laboratories involved in the process of fixation or embedding of the tumor sample was evaluated.
|
Up to 6 months
|
|
Time From Sampling to Fixation- Pre-analytical Method
Tidsram: Up to 6 months
|
Time taken from the sampling to the fixation of the tumor sample was reported in range of 0-2 hours, 2-6 hours, >6 hours and unknown.
Number of samples falling in each of the class were reported.
|
Up to 6 months
|
|
Type of Fixative Used- Pre-analytical Method
Tidsram: Up to 6 months
|
The different types of fixative Excell, formol, alcohol formol acetic acid and other, used to fix the tumor samples were reported.
|
Up to 6 months
|
|
Fixation Duration by Pre-analytical Method
Tidsram: Up to 6 months
|
Fixation duration is defined as the amount of time required in hours for the fixation of a samples.
The fixation duration was categorized as <6 hours, 6-24 hours and >24 hours and unknown.
Number of samples falling in each category were reported
|
Up to 6 months
|
|
Slice Thickness by Pre-analytical Method
Tidsram: Up to 6 months
|
Slice thickness of all the tumour samples was measured.
The slice thickness was measured in micrometer.
|
Up to 6 months
|
|
Dewaxing by Pre-analytical Method
Tidsram: Up to 6 Months
|
Dewaxing is a method to recover the DNA from samples.
Dewaxing information was collected as "Yes, No or Missing"
|
Up to 6 Months
|
|
Necrosis Percentage Determination by Pre-analytical Method
Tidsram: Up to 6 months
|
The percentage of necrosis defined as the death of one or more cells in the analysed zone was reported.
|
Up to 6 months
|
|
Percentage of Tumor Cells by Pre-analytical Method
Tidsram: Up to 6 months
|
The percentage of tumor cells in the given tumor sample were reported.
|
Up to 6 months
|
|
Tumor Samples With Presence of Melanin by Pre-analytical Method
Tidsram: Up to 6 months
|
The tumor samples with presence of melanin were categorized as Important, Few, Medium and Absent.
|
Up to 6 months
|
|
DNA Extraction - Extraction Method by Pre-analytical Method
Tidsram: Up to 6 months
|
This method assessed DNA from the tumor samples was extracted by Automated method or Manual method.
|
Up to 6 months
|
|
Median DNA Elution Volume by Pre-analytical Method
Tidsram: Up to 6 months
|
Median DNA elution volume microliters [mcl] was reported.
|
Up to 6 months
|
|
Mean DNA Concentration by Pre-analytical Method
Tidsram: Up to 6 months
|
The DNA concentration in the tissue elute was measured in nanogram per microliter (ng/mcL).
|
Up to 6 months
|
|
Amount of DNA by Pre-analytical Method
Tidsram: Up to 6 months
|
The total DNA concentration extracted from the tissue was measured in nanogram (ng).
|
Up to 6 months
|
|
Size of Amplicons Used by "In-house" Analytical Method
Tidsram: Up to 6 months
|
The method described the size of amplicon used.
It was measured in base pairs (bp).
|
Up to 6 months
|
|
Method of Mutation Detection by "In-house" Analytical Method
Tidsram: Up to 6 months
|
Allele-specific PCR, High Resolution Melting (HRM) + Sanger sequencing, Pyrosequencing, Sanger sequencing, Real time PCR, SNaPshot were used for BRAF V600 mutation detection.
|
Up to 6 months
|
|
Number of Samples Punched in In-house Analytical Method
Tidsram: Up to 6 months
|
Total number of samples for whom punch was used in 'in-house analytical' method are reported.
|
Up to 6 months
|
|
Mean Number of Slices Per Sample Used for "In-house"- Analytical Method
Tidsram: Up to 6 months
|
The mean of number of slices per sample when no punch was used are reported.
|
Up to 6 months
|
|
Median Time Between Receipt of Samples and Determination of Result by "In-house" Analytical Method
Tidsram: Up to 6 months
|
This In-house analytical method measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by "In-house" Analytical Method
Tidsram: Up to 6 months
|
The working time required by the technician from the time of DNA extraction to the time to obtain the results was measured in hours.
|
Up to 6 months
|
|
Mean DNA Concentration as Measured by COBAS 4800 BRAF V600 Mutation Test-Analytical Method
Tidsram: Up to 6 months
|
The DNA concentration as assessed by COBAS 4800 BRAF V600 Mutation assay was reported.
The unit used to measure the DNA concentration was nanogram/microlitre (ng/mcl)
|
Up to 6 months
|
|
Punch Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Tidsram: Up to 6 months
|
The punch done during Cobas 4800 BRAF V600 Mutation Test on the sample was described as Yes or No.
|
Up to 6 months
|
|
Number of Slices Used When No Punch Was Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Tidsram: Up to 6 months
|
This describes the Cobas 4800 BRAF V600 Mutation Test, for the mean of number of slices when No punch method, was used.
Of the 420 samples, punch was Yes, for 45 samples and punch was No, for 375 samples.
|
Up to 6 months
|
|
Median Time Between Receipt of Sample and Determination of Result by Cobas 4800 BRAF V600 Mutation Test -Analytical Method
Tidsram: Up to 6 months
|
This analytical method for cobas 4800 BRAF V600 Mutation Test measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by Cobas 4800 BRAF V600 Mutation Test - Analytical Method
Tidsram: Up to 6 months
|
This cobas 4800 BRAF V600 Mutation Test analytical method measures the working time required by the technician from the time of DNA extraction to the time to obtain the results.
The time duration was measured in hours.
|
Up to 6 months
|
|
Management of Discordance- Method Used to Manage Discordance
Tidsram: Up to 6 months
|
Crossing DNA, DNA from In-House method analysed with cobas, SNaPshot, DNA from cobas analysed with In-House method, external site control test, Sanger sequencing, Kit CE-IVD Therascreen RGQ Qiagen, Kit Therascreen RGQ BRAF + Pyrosequencing by another platform (PF), Pyrosequencing, Mutation detection On Another Block, (primitive tumor [prm.
tmr]), Sequencing And Therascreen kit (Qiagen) were used for management of discordance between "in-house" method and Cobas 4800 mutation test.
|
Up to 6 months
|
|
Management of Discordance-Final Result for BRAF V600 Mutation Detection
Tidsram: Up to 6 months
|
The final results obtained by discordance management of the 28 discordant samples were BRAF V600 mutation, No BRAF V600 mutation and Non-evaluable.
These results were further assessed by the Investigator and interpreted as final result.
|
Up to 6 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2012
Primärt slutförande (Faktisk)
1 april 2013
Avslutad studie (Faktisk)
1 april 2013
Studieregistreringsdatum
Först inskickad
6 december 2012
Först inskickad som uppfyllde QC-kriterierna
6 december 2012
Första postat (Uppskatta)
7 december 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
28 mars 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
25 februari 2016
Senast verifierad
1 november 2015
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ML28471
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .